GlassScriptPhysician profile
Jamie E Givens
NPI 1871634428
$3,438.09
in general payments reported to CMS, 2019-2025
26 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.33 · 2023: $949 · 2024: $1,173 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $533.76 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $454.50 | 2023-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $352.06 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $311.24 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $309.93 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.01 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Insulet Corporation | $164.97 | 2023-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $151.08 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $134.62 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $93.87 | 2023-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $78.39 | 2023-2025 | Korlym |
| Abbvie INC. | $77.78 | 2023-2024 | |
| Radius Health, INC. | $72.10 | 2025 | Tymlos |
| Medtronic, INC. | $68.81 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Amgen INC. | $56.29 | 2024-2025 | Evenity, Prolia, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.28 | 2025 | Dupixent |
| Ascendis Pharma Endocrinology INC | $47.93 | 2025 | Yorvipath |
| Jazz Pharmaceuticals INC. | $39.24 | 2023 | |
| Cequr Corporation | $34.42 | 2024-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $29.32 | 2023-2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $29.20 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $28.19 | 2025 | |
| Averitas Pharma INC. | $25.41 | 2025 | Qutenza |
| Sequel Med Tech, LLC | $23.17 | 2025 | Twiist |
| Antares Pharma, INC. | $16.62 | 2024 | Xyosted |
| Intra-Sana Laboratories | $13.90 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Givens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.